Table 1 Cumulative risk of CIN2 + and CIN3 + stratified by age or cytology among HPV-positive women at baseline after 3-year follow-up a
Total (N) | CIN2+ | CIN3+ | ||||||
|---|---|---|---|---|---|---|---|---|
Cases (n) | Risk (95% CI), % | Cases (n) | Risk (95% CI), % | |||||
HC2 positive | ||||||||
Age (years) | 25–29 | 12 | 5 | 41.67 (19.33–68.05) | 3 | 25 (8.89–53.23) | ||
30–39 | 90 | 25 | 27.78 (19.58–37.8) | 16 | 17.78 (11.25–26.95) | |||
40–49 | 212 | 56 | 26.42 (20.94–32.74) | 30 | 14.15 (10.09–19.48) | |||
50–59 | 194 | 31 | 15.98 (11.49–21.79) | 16 | 8.25 (5.14–12.98) | |||
60–71 | 50 | 9 | 18 (9.77–30.8) | 6 | 12 (5.62–23.8) | |||
Cytology | NILM | 406 | 62 | 15.27 (12.1-19.09) | 33 | 8.13 (5.85–11.2) | ||
Low-gradeb | 94 | 21 | 22.34 (15.1-31.75) | 7 | 7.45 (3.66–14.59) | |||
High-gradec | 58 | 43 | 74.14 (61.62–83.66) | 31 | 53.45 (40.8-65.67) | |||
DH3-HPVdpositive | ||||||||
Age (years) | 25–29 | 14 | 5 | 35.71 (16.34–61.23) | 3 | 21.43 (7.57–47.59) | ||
30–39 | 93 | 25 | 26.88 (18.92–36.67) | 16 | 17.2 (10.87–26.13) | |||
40–49 | 215 | 57 | 26.51 (21.06–32.78) | 30 | 13.95 (9.95–19.22) | |||
50–59 | 207 | 31 | 14.98 (10.76–20.48) | 16 | 7.73 (4.81–12.19) | |||
60–71 | 54 | 9 | 16.67 (9.03–28.74) | 6 | 11.11 (5.19–22.19) | |||
Cytology | NILM | 430 | 63 | 14.65 (11.62–18.31) | 33 | 7.67 (5.51–10.58) | ||
Low-gradeb | 94 | 21 | 22.34 (15.1-31.75) | 7 | 7.45 (3.66–14.59) | |||
High-gradec | 59 | 43 | 72.88 (60.4-82.56) | 31 | 52.54 (40.04–64.73) | |||
HPV16/18 positive | ||||||||
Age (years) | 25–29 | 5 | 4 | 80 (37.5-96.38) | 3 | 60 (23.07–88.24) | ||
30–39 | 24 | 11 | 45.83 (27.89–64.92) | 6 | 25 (12-44.9) | |||
40–49 | 50 | 26 | 52 (38.51–65.2) | 15 | 30 (19.1-43.75) | |||
50–59 | 39 | 14 | 35.9 (2.74–51.58) | 8 | 20.51 (10.78–35.53) | |||
60–71 | 15 | 4 | 26.67 (10.9-51.95) | 2 | 13.33 (3.73–37.88) | |||
Cytology | NILM | 85 | 26 | 30.59 (21.81–41.05) | 14 | 16.47 ()10.07–25.77 | ||
Low-gradeb | 22 | 11 | 50 (30.72–69.28) | 2 | 9.09 (2.53–27.81) | |||
High-gradec | 26 | 22 | 84.62 (66.47–93.85) | 18 | 69.23 (50.01–83.5) | |||
Other hrHPVepositive | ||||||||
Age (years) | 25–29 | 9 | 1 | 11.11 (1.99–43.5) | 0 | 0 (0-29.91) | ||
30–39 | 69 | 14 | 20.29 (12.49–31.22) | 10 | 14.49 (8.07–24.66) | |||
40–49 | 165 | 31 | 18.79 (13.57–25.43) | 15 | 9.09 (5.59–14.46) | |||
50–59 | 168 | 17 | 10.12 (6.41–15.61) | 8 | 4.76 (2.43–9.11) | |||
60–71 | 39 | 5 | 12.82 (5.6-26.71) | 4 | 10.26 (4.06–23.58) | |||
Cytology | NILM | 345 | 37 | 10.72 (7.88–14.43) | 19 | 5.51 (3.56–8.44) | ||
Low-gradeb | 72 | 10 | 13.89 (7.72–23.71) | 5 | 6.94 (3-15.24) | |||
High-gradec | 33 | 21 | 63.64 (46.62–77.82) | 13 | 39.39 (24.68–56.31) | |||